1 Department of Hematology and Stem Cell Transplant, Army Hospital (Research & Referral), Delhi, India.
2 Department of Internal Medicine (Clinical Hematology Division), PGIMER, Chandigarh, India.
J Adolesc Young Adult Oncol. 2019 Feb;8(1):94-97. doi: 10.1089/jayao.2018.0007. Epub 2018 Nov 1.
The data on adolescent and young adult chronic myeloid leukemia (AYA-CML) from the Indian subcontinent are scarce. We studied characteristics of AYA-CML through a retrospective analysis of 1950 CML patients registered to a tertiary care hospital in Northern India. AYA-CML represented 22.1% of all CML patients, with cumulative overall survival (OS) of 84%, and 1 and 8 years OS of 94.2% and 74.2%, respectively. Of all cases, 8.91% patients had advanced disease at the time of diagnosis, and 13.95% had myelofibrosis in the diagnostic marrow, 79.6% had complete cytogenetic response (CCyR), and 84.5% had major molecular response (MMR). Loss of CCyR and MMR was noted in 37.2% and 28.4%, respectively. The cumulative OS was significantly better in patients on patient assistance program, and they were initiated on therapy within 3 months of symptom onset.
来自印度次大陆的青少年和年轻成人慢性髓细胞白血病（AYA-CML）的数据很少。我们通过对印度北部一家三级护理医院登记的 1950 例 CML 患者进行回顾性分析，研究了 AYA-CML 的特征。AYA-CML 占所有 CML 患者的 22.1%，累积总生存率（OS）为 84%，1 年和 8 年 OS 分别为 94.2%和 74.2%。所有病例中，8.91%的患者在诊断时处于晚期疾病状态，13.95%的患者在诊断性骨髓中有骨髓纤维化，79.6%的患者有完全细胞遗传学缓解（CCyR），84.5%的患者有主要分子缓解（MMR）。分别有 37.2%和 28.4%的患者出现 CCyR 和 MMR 丧失。接受患者援助计划的患者的累积 OS 明显更好，他们在症状出现后 3 个月内开始接受治疗。
